A Phase II, Open-label, Single Arm, Investigator-initiated Trail of An Anti-PD-1 Inhibitor SHR-1210 in Combination With Apatinib in the Perioperative Treatment of Hepatocellular Carcinoma
Latest Information Update: 05 Aug 2022
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms HCC-009
Most Recent Events
- 05 Aug 2022 Last checked against ClinicalTrials.gov record.
- 08 Jun 2021 Status changed from recruiting to completed, results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology